NYSE$DD

DuPont de Nemours Inc. · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

DuPont exceeded expectations through disciplined pricing and operational excellence, navigating global supply chain challenges and inflationary pressures, while underlying demand in key end-markets remained strong.

DuPont reported Q2 2022 financial results ahead of expectations, with net sales of $3.3 billion, a 7% increase from the previous year, and organic sales growth of 9%. The company's adjusted EPS increased by 11% to $0.88, and operating EBITDA increased by 6% to $829 million.

  • Net sales increased 7% to $3.3 billion; organic sales increased 9% versus year-ago period.
  • GAAP income from continuing operations was $365 million; operating EBITDA of $829 million increased 6% versus year-ago period; consistent operating EBITDA margin year-over-year.
  • GAAP EPS from continuing operations was $0.71; adjusted EPS of $0.88 increased 11% versus year-ago period.
  • Approximately $665 million of capital was returned to shareholders through $500 million in share repurchases and ~$165 million in dividends.

Headline financials

Total Revenue

$3.32B

Previous: $4.14B-19.7%
EPS (adj)

$0.88

Previous: $1.06-17.0%
Operating EBITDA

$829M

Previous: $1.06B-21.8%
EBITDA margin

25.0%

Previous: 4.6%+443.5%
Free Cash Flow

$787M

Previous: $478M+64.6%
Net Income

$787M

Previous: $478M+64.6%
Operating Income

-$2.85B

Previous: -$3.16B+9.8%
Gross Profit

$1.17B

Previous: $1.48B-20.7%
Cash & Equivalents

$1.44B

Previous: $3.96B-63.7%
Total Assets

$44.4B

Previous: $45.8B-3.1%

Revenue & EPS history

DuPont · Revenue · Quarterly

$3.32B

Q2 2022-19.7%vs Q2 2021
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Forward guidance

DuPont narrowed its full year 2022 adjusted EPS guidance from $3.20-$3.50 to $3.27-$3.43 while maintaining the mid-point of our previous range. The updated full year 2022 guidance ranges for net sales and operating EBITDA reflect incremental foreign currency headwinds and the removal of contribution from the Biomaterials business, which was divested on May 31, 2022.

Tailwinds

  • Demand and overall order trends in key end-markets remain solid.
  • Third quarter net sales are expected to be up 2 percent at the mid-point of the range, or up high single-digits on an organic basis.
  • Focus on execution
  • Strong first half 2022 results reflect positively on the secular end-markets
  • Maintaining the mid-point of our previous range

Headwinds

  • Future uncertainties continue to exist including continued inflationary pressure.
  • Challenging supply chains
  • U.S. dollar strength against global currencies.
  • Third quarter 2022 net sales and operating EBITDA to be slightly weaker than second quarter 2022
  • Negative impact during the third quarter on operating EBITDA of approximately $15 million from unplanned downtime at our Spruance site

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+0.8%

Avg return

Earnings day

+1.0%

Avg return

5 days after

+0.0%

Avg return

30 days after

63%

40 / 64 earnings

Positive

+12.5%

Q3 2021

Best reaction

-11.3%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%+9.6%+4.0%
Q4 2025+4.9%+6.6%-3.7%
Q3 2025-1.1%+1.9%+2.2%
Q1 2025+1.7%-2.3%+1.1%
Q4 2024+6.8%+9.2%-1.8%
Q3 2024+3.0%+2.8%-0.1%
Q2 2024+2.8%-3.2%+4.8%
Q1 2024+7.2%+8.3%+13.3%
Q4 2023+8.6%-15.0%-6.3%
Q3 2023-6.5%-4.6%-0.6%
Q2 2023+0.1%+1.3%+1.2%
Q1 2023-7.2%-5.6%-2.8%
Q4 2022+6.3%+4.8%-2.1%
Q3 2022+8.6%+14.7%+13.1%
Q2 2022-3.4%-2.2%-8.3%
Q1 2022+4.4%-0.7%+4.4%
Q4 2021+8.1%+5.2%-4.4%
Q3 2021+12.5%+12.9%+5.7%
Q2 2021-0.5%+1.9%-1.0%
Q1 2021+3.4%+5.8%+9.1%
Q4 2020-7.2%-2.3%-14.3%
Q3 2020+1.7%+6.6%+15.4%
Q2 2020-3.7%-4.3%+3.0%
Q1 2020-1.5%+4.9%+22.9%
Q4 2019-11.3%-8.6%-25.6%
Q3 2019+6.2%+10.4%-1.2%
Q2 2019-4.3%-5.0%-5.9%
Q1 2019-6.5%-13.9%-18.2%
Q4 2018-9.8%-8.5%-10.0%
Q3 2018+7.1%+7.6%+7.3%
Q2 2018-1.7%+0.3%+3.2%
Q1 2018+1.5%+1.2%+4.2%
Q4 2017-6.2%-4.9%-9.5%
Q3 2017-3.0%-3.0%-3.2%
Q2 2017+0.3%-0.8%-2.8%
Q1 2017+2.4%-0.0%-3.5%
Q4 2016+5.4%+7.3%+10.9%
Q3 2016-0.9%-0.6%-0.3%
Q2 2016+0.7%+0.8%+1.4%
Q1 2016+2.0%
Q4 2015-1.8%
Q3 2015+1.8%
Q2 2015+3.9%
Q1 2015-0.1%
Q4 2014-3.4%
Q3 2014+1.9%
Q2 2014+3.9%
Q1 2014+0.5%
Q4 2013+3.8%
Q3 2013-0.8%
Q2 2013-0.6%
Q1 2013+3.8%
Q4 2012+4.5%
Q3 2012+1.3%
Q2 2012+0.0%
Q1 2012+1.0%
Q4 2011+3.6%
Q3 2011-9.4%
Q2 2011+1.5%
Q1 2011+1.7%
Q4 2010+2.1%
Q3 2010+1.8%
Q2 2010-3.7%
Q1 2010+1.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro